YFV Protein, Middle East Markets, Gene Editing and "Data Lakes" are among Developments at First Day of AACC 2017 in San Diego
ROCKVILLE, Md., Aug. 1, 2017 /PRNewswire/ -- The laboratory industry's largest meeting, along with associated IVD equipment vendors, are meeting this week in San Diego to discuss new ideas and demonstrate new products. According to healthcare market researcher Kalorama information, there are already developments at the meeting's first day as companies made announcement and the plenary session was held. Improved lab developed test equipment, a new yellow fever reagent, the Middle East IVD Market, and promise of CRISPR highlighted the first day of the American Association for Clinical Chemistry Meeting (AACC 2017) in San Diego, California. The New York City-based healthcare research firm covers IVD in its Worldwide Market for In Vitro Diagnostics, 10th Edition, a comprehensive in vitro diagnostics market research study.
Kalorama Information noted the following developments :
-- New YFV Protein: Aalto Bio Reagents announced their first-to-market
recombinant Yellow Fever Virus (YFV) protein at AACC in San Diego from
1st - 3rd August. Yellow Fever virus is a potentially fatal
mosquito-borne flavivirus which is prevalent in tropical and subtropical
locations in South America and Africa. It is the next flavivirus
threatening the population of Brazil, with local health officials
reporting a sharp rise in cases this year. The company, founded in
1978, Aalto Bio Reagents is a developer and provider of raw materials to
the in- vitro diagnostics industry and to research laboratories
globally. Infectious disease is one of the most important markets for
IVD, and Kalorama covers this extensively in its market study on this
area.
-- Order-to-Report Multiplex PCR: Seegene Inc. announced a Random Access
System. The company says the system can provide order-to-report on the
same day by simultaneously performing high multiplex real-time PCR
testing on a single platform, regardless of specimen type or assays. .
Rapid, accurate diagnosis and prompt treatment are especially critical
for a successful treatment of infectious diseases such as tuberculosis,
acute diarrhea, sepsis or meningitis. The company said most existing
MDx systems are unable to perform same-day reporting for same day
treatment, because clinical laboratories typically perform testing after
a sufficient number of specimens are collected.
-- Simplified LDT for Leukemia and Lymphoma: Beckman Coulter presented
its ClearLLab reagents at the meeting, these products deliver the first
preformulated, IVD antibody cocktails for leukemia and lymphoma**
immunophenotyping in the clinical lab. Previously, labs would have had
to make and validate their own antibody cocktails. ClearLLab simplifies
and standardizes the process. The products are cleared via the FDA De
Novo Process for in vitro diagnostic use in the US. For clinical
laboratories it means they no longer have to develop their own
laboratory developed test (LDT), a technically demanding, manual,
time-consuming, and potentially error-prone process.
-- Focus on Middle East IVD: Long a target for IVD companies seeking
emerging market growth, the Middle East will now have a laboratory
association with global pull. AACC announced on Monday that it will
launch a new laboratory medicine conference and expedition next spring -
AACC Middle East. AACC Middle East will showcase AACC's
globally-renowned education and scientific programs paired with a
dynamic exposition in Abu Dhabi, United Arab Emirates (UAE), March
22-24, 2018. The scientific program will feature experts from the U.S.
and the Middle East, sharing knowledge and innovation. Attendees will
meet and network with experts in the field, and engage with their peers
during the scientific program highlighting recent advances in laboratory
medicine. Kalorama's report on the Middle East IVD market can be found
at https://www.kaloramainformation.com/IVD-Middle-East-10336235/
-- Connected Lab, "Data Lakes": Roche's booth at AACC 2017 features a
virtual reality tour that will demonstrate the company's concept of
connected lab . "The idea of a connected lab begins with an integrated
core lab with connected automation." said Jack Phillips, president and
CEO of Roche Diagnostics Corporation in a press release. "But it also
involves linking instruments to data lakes, laboratories to physicians,
and high-medical-value tests to clinical insights to help improve the
way physicians manage their patients." A data lake is a storage
repository that holds a vast amount of raw data in its native format and
doesn't structure it and define how it will be structured, until the
data is needed. The company is the largest IVD company, according to
Kalorama Information and competes in nearly every IVD sub market; while
it is also demonstrating a new cobas e 801 high-volume immunoassay
platform that Roche says provides nearly twice the throughput on the
same footprint as its predecessor.
-- CRISPR/ Cas9: Gene editing was also a large focus at the meeting's
first day. Jennifer Doudna, PhD, a geneticist and a co-creator along
with Emmanuelle Carpenter, PhD, of the CRISPR-Cas9 technology, delivered
the Wallace H. Coulter Lectureship Award plenary on Sunday with her
talk, "CRISPR Biology, Technology & Ethics: The Future of Genome
Engineering." Doudna discussed her "molecular scalpel for genomes."
She intrigued the audience by reviewing the intricate bacterial CRISPR
adaptive immune system and how her lab harnessed its power to edit
genes. She discussed the work that is ongoing aimed at making CRISPR
more amenable to fighting disease. CRISPR/Cas9 is a revolutionary
approach that enables rapid, economical model generation through precise
genome editing. Every day, new studies continue to leverage the
potential of CRISPR to generate novel strategies for modeling diseases
and assessing therapeutic intervention. The tool is used in nature by
bacteria to adapt to their environment.
Kalorama covers the IVD market in its report, The Worldwide Market for In Vitro Diagnostics, 10th Edition: www.kaloramainformation.com/Worldwide-Vitro-Diagnostic-10206771.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.
Press Contact:
Bruce Carlson
212 807 2262
bcarlson@marketresearch.com
View original content with multimedia:http://www.prnewswire.com/news-releases/yfv-protein-middle-east-markets-gene-editing-and-data-lakes--are-among-developments-at-first-day-of-aacc-2017-in-san-diego-300497588.html
SOURCE Kalorama Information
